ARTIRIA Medical

Executive Summary

ARTIRIA Medical is a Swiss medtech company based in Lausanne, founded in 2019, that develops advanced catheter and guidewire technologies to enhance neurointerventional procedures, particularly for stroke treatment. By improving navigation and device control, the company aims to overcome current limitations in neurovascular interventions and enable more effective, less invasive treatments. The company is in the 'Approved' stage, suggesting its core technology has received regulatory clearance (likely CE mark or FDA 510(k)), positioning it for market entry. With a focus on the growing neurovascular device market, ARTIRIA's innovations could address unmet needs in acute ischemic stroke and other cerebrovascular diseases. Although specific financial details are undisclosed, the company's strategic location in Switzerland's medtech hub and its specialized pipeline suggest strong potential for clinical adoption and partnership opportunities.

Upcoming Catalysts (preview)

• Q4 2026Regulatory Approval for Next-Generation Device in Europe (CE Mark)75% success
• Q3 2026Strategic Partnership or Distribution Agreement with Major Neurovascular Player60% success
• Q2 2027Publication of First-in-Human Clinical Data Demonstrating Improved Outcomes70% success